Erasca/$ERAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Ticker
$ERAS
Sector
Primary listing
Employees
103
Headquarters
Website
Erasca Metrics
BasicAdvanced
$454M
-
-$0.45
1.07
-
Price and volume
Market cap
$454M
Beta
1.07
52-week high
$3.10
52-week low
$1.01
Average daily volume
882K
Financial strength
Current ratio
11.035
Quick ratio
10.755
Long term debt to equity
12.012
Total debt to equity
13.277
Profitability
EBITDA (TTM)
-131.226
Management effectiveness
Return on assets (TTM)
-17.92%
Return on equity (TTM)
-31.16%
Valuation
Price to book
1.22
Price to tangible book (TTM)
1.22
Price to free cash flow (TTM)
-4.329
Free cash flow yield (TTM)
-23.10%
Free cash flow per share (TTM)
-0.37
Growth
Earnings per share change (TTM)
-52.06%
3-year earnings per share growth (CAGR)
-29.54%
What the Analysts think about Erasca
Analyst ratings (Buy, Hold, Sell) for Erasca stock.
Bulls say / Bears say
Erasca’s strong balance sheet—with $411.1 million in cash and marketable securities as of March 31, 2025—extends its financial runway into the second half of 2028, lessening immediate financing concerns.
In May 2025, Erasca received FDA clearance of the IND for ERAS-0015 and filed the IND for ERAS-4001, allowing both programs to begin Phase 1 trials with initial monotherapy data expected in 2026, highlighting the company’s pipeline execution.
The SEACRAFT-2 Phase 3 trial of naporafenib plus trametinib in NRAS-mutant melanoma is moving forward with FDA Fast Track status and Stage 1 randomized data due in H2 2025, positioning Erasca for a possible first-to-market approval in a high-need area.
With no products on the market, Erasca reported zero revenue and R&D expenses of $26 million in Q1 2025, signaling continued heavy cash burn ahead of any commercial launch.
Initial human data for both ERAS-0015 and ERAS-4001 are not expected until 2026, prolonging clinical and regulatory uncertainty and heightening binary risks for investors.
Erasca’s stock has dropped about 47% over the past six months, hitting a 52-week low of $1.23 as the market remains skeptical of near-term catalysts.
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Erasca Financial Performance
Revenues and expenses
Erasca Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Erasca stock?
Erasca (ERAS) has a market cap of $454M as of September 16, 2025.
What is the P/E ratio for Erasca stock?
The price to earnings (P/E) ratio for Erasca (ERAS) stock is 0 as of September 16, 2025.
Does Erasca stock pay dividends?
No, Erasca (ERAS) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Erasca dividend payment date?
Erasca (ERAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Erasca?
Erasca (ERAS) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.